Who are DEB-TACE plus PD-1 inhibitor's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deb-tace-plus-pd-1-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

DEB-TACE plus PD-1 inhibitor — Competitive Intelligence Brief

DEB-TACE plus PD-1 inhibitor (DEB-TACE plus PD-1 inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: locoregional chemotherapy + immune checkpoint inhibitor. Area: Oncology.

phase 3 Combination therapy: locoregional chemotherapy + immune checkpoint inhibitor PD-1 (programmed death receptor 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DEB-TACE plus PD-1 inhibitor (DEB-TACE plus PD-1 inhibitor) — Guangxi Medical University. DEB-TACE delivers chemotherapy directly to liver tumors via embolic beads while a PD-1 inhibitor simultaneously unleashes anti-tumor immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DEB-TACE plus PD-1 inhibitor TARGET	DEB-TACE plus PD-1 inhibitor	Guangxi Medical University	phase 3	Combination therapy: locoregional chemotherapy + immune checkpoint inhibitor	PD-1 (programmed death receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: locoregional chemotherapy + immune checkpoint inhibitor class)

Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DEB-TACE plus PD-1 inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/deb-tace-plus-pd-1-inhibitor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab